![Wenbin Dang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wenbin Dang
Corporate Officer/Principal at Amerigen Pharmaceuticals Ltd.
Profile
Wenbin Dang is a professional who currently holds the position of Senior Vice President-Product Development at Amerigen Pharmaceuticals Ltd.
She previously worked as Director-Formulation & Technology Development at Cardinal Health, Inc., Principal at Alkermes, Inc. and Guilford Pharmaceuticals, Inc., and Vice President-Product Development at Catalent Pharma Solutions, Inc. Dr. Dang holds a doctorate degree from The Johns Hopkins University.
Wenbin Dang active positions
Companies | Position | Start |
---|---|---|
Amerigen Pharmaceuticals Ltd.
![]() Amerigen Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Amerigen Pharmaceuticals Ltd. engages in the development, manufacturing, and sale of generic pharmaceutical products. The company was founded in 2007 and is headquartered in Lyndhurst, NJ. | Corporate Officer/Principal | 31/12/2009 |
Former positions of Wenbin Dang
Companies | Position | End |
---|---|---|
Alkermes, Inc.
![]() Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
CARDINAL HEALTH, INC. | Corporate Officer/Principal | - |
Guilford Pharmaceuticals, Inc.
![]() Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | - |
Catalent Pharma Solutions, Inc.
![]() Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Corporate Officer/Principal | - |
Training of Wenbin Dang
The Johns Hopkins University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
CARDINAL HEALTH, INC. | Distribution Services |
Private companies | 4 |
---|---|
Amerigen Pharmaceuticals Ltd.
![]() Amerigen Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Amerigen Pharmaceuticals Ltd. engages in the development, manufacturing, and sale of generic pharmaceutical products. The company was founded in 2007 and is headquartered in Lyndhurst, NJ. | Health Technology |
Catalent Pharma Solutions, Inc.
![]() Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Health Technology |
Guilford Pharmaceuticals, Inc.
![]() Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Alkermes, Inc.
![]() Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Wenbin Dang